Advertisement
Advertisement
AKTX
Akari Therapeutics plc ADR (0.01 USD)
6.25
USDSponsored
-0.33
-5.02%
May 08, 15:59 UTC -4
Closed
After-Market
6.26
+0.01
+0.16%
AKTX Earnings Reports
Positive Surprise Ratio
AKTX beat 9 of 18 last estimates.
50%
Next Report
Next Week
Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$1.40
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
--
/--
Akari Therapeutics plc ADR (0.01 USD) earnings per share and revenue
On Mar 30, 2026, AKTX reported earnings of 0.00 USD per share (EPS) for Q4 25, beating the estimate of -1.53 USD, resulting in a 100.00% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +6.41% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of -1.40 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Werewolf Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+3.68%
LeonaBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$2.47
Actual
-$1.73
Surprise
+30.20%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Xenon Pharmaceuticals Inc
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.17
Surprise
+3.14%
Palvella Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.95
Actual
-$1.20
Surprise
-26.21%
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
May 07, 2026 For Q1 26
Estimate
$0.00
Actual
-$0.01
Surprise
-249.25%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
Zura Bio Limited Class A Ordinary Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.17
Actual
-$0.22
Surprise
-23.94%
Verastem, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.47
Actual
-$0.46
Surprise
+2.19%
FAQ
What were Akari Therapeutics plc ADR (0.01 USD)'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Akari Therapeutics plc ADR (0.01 USD) reported EPS of $0.00, beating estimates by 100%, and revenue of $0.00, 0% as expectations.
How did the market react to Akari Therapeutics plc ADR (0.01 USD)'s Q4 2025 earnings?
The stock price moved up 6.41%, changed from $4.84 before the earnings release to $5.15 the day after.
When is Akari Therapeutics plc ADR (0.01 USD) expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Akari Therapeutics plc ADR (0.01 USD)'s next earnings report?
Based on 4
analysts, Akari Therapeutics plc ADR (0.01 USD) is expected to report EPS of -$1.40 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement